patent for semaglutide Semaglutide's expires today. What does it mean patients, pharma players and Novo Nordisk? The Heavy Price of GLP-1

Ingredients: semaglutide

Due to their prolonged presence, the weight loss drugs are more potent and have a stronger effect on appetite suppression than the GLP-1 that is naturally produced in the body

We begin at a low weekly dose and adjust every few weeks based on your response

Baseline Conditions: Consider baseline sleep quality, stress state, and physiological conditions which may influence DSIP responsiveness

Patients who might be considered for GLP-1 therapy (within licensed indications) and who may experience secondary benefits for binge eating behaviours include: Individuals with binge eating disorder and type 2 diabetes , where GLP-1 agonists address the primary diabetes indication whilst potentially helping with eating patterns Those with BED and obesity who meet NHS eligibility criteria for weight management medications (as defined by NICE TA875 for semaglutide or TA664 for liraglutide, which are narrower than the marketing authorisation) Patients who have not responded adequately to psychological interventions such as cognitive behavioural therapy (CBT) and who have concurrent metabolic conditions Those experiencing significant food cravings and loss-of-control eating as part of their weight management challenges However, important cautions and considerations apply